Division of Neonatology, Department of Pediatrics (T.L., M.Z., A.B.B.), Department of Respiratory Care (M.H.T.), and Center for Perinatal Biology (H.S., S.M.W., G.G.P., A.B.B.), Loma Linda University School of Medicine, Loma Linda, California; Neonatal Redox Biology Laboratory, Division of Neonatology, University of Alabama at Birmingham, Birmingham, Alabama (Q.L., T.E.T.); and Department of Chemistry, University of California, Riverside, California (D.B.).
Division of Neonatology, Department of Pediatrics (T.L., M.Z., A.B.B.), Department of Respiratory Care (M.H.T.), and Center for Perinatal Biology (H.S., S.M.W., G.G.P., A.B.B.), Loma Linda University School of Medicine, Loma Linda, California; Neonatal Redox Biology Laboratory, Division of Neonatology, University of Alabama at Birmingham, Birmingham, Alabama (Q.L., T.E.T.); and Department of Chemistry, University of California, Riverside, California (D.B.)
Mol Pharmacol. 2018 May;93(5):427-437. doi: 10.1124/mol.117.110957. Epub 2018 Feb 23.
Glutathione-liganded binuclear dinitrosyl iron complex (glut-BDNIC) has been proposed to be a donor of nitric oxide (NO). This study was undertaken to investigate the mechanisms of vasoactivity, systemic hemodynamic effects, and pharmacokinetics of glut-BDNIC. To test the hypothesis that glut-BDNICs vasodilate by releasing NO in its reduced [nitroxyl (HNO)] state, a bioassay method of isolated, preconstricted ovine mesenteric arterial rings was used in the presence of selective scavengers of HNO or NO free radical (NO); the vasodilatory effects of glut-BDNIC were found to have characteristics similar to those of an HNO donor and markedly different than an NO donor. In addition, products of the reaction of glut-BDNIC with CPTIO [2-(4-carboxyphenyl)-4,4,5-tetramethyl imidazoline-1-oxyl-3-oxide] were found to have electron paramagnetic characteristics similar to those of an HNO donor compared with an NO donor. In contrast to -nitroso-glutathione, which was vasodilative both in vitro and in vivo, the potency of glut-BDNIC-mediated vasodilation was markedly diminished in both rats and sheep. Wire myography showed that plasma albumin contributed to this loss of hypotensive effects, an effect abolished by modification of the cysteine-thiol residue of albumin. High doses of glut-BDNIC caused long-lasting hypotension in rats that can be at least partially attributed to its long circulating half-life of ∼44 minutes. This study suggests that glut-BDNIC is an HNO donor, and that its vasoactive effects are modulated by binding to the cysteine residue of plasma proteins, such as albumin.
谷胱甘肽配位双核亚硝酰基铁配合物(glut-BDNIC)被认为是一氧化氮(NO)的供体。本研究旨在探讨 glut-BDNIC 的血管活性、全身血流动力学效应和药代动力学机制。为了验证 glut-BDNIC 通过其还原态(亚硝酰基(HNO))释放 NO 来舒张血管的假设,使用分离的预先收缩的羊肠系膜动脉环的生物测定方法,在存在 HNO 或 NO 自由基(NO)的选择性清除剂的情况下,发现 glut-BDNIC 的血管舒张作用具有类似于 HNO 供体的特征,并且与 NO 供体明显不同。此外,glut-BDNIC 与 CPTIO [2-(4-羧基苯基)-4,4,5-四甲基咪唑啉-1-氧-3-氧化物]的反应产物被发现具有与 HNO 供体相似的电子顺磁共振特征,而与 NO 供体不同。与体内外均具有血管舒张作用的 -亚硝基-谷胱甘肽不同,glut-BDNIC 介导的血管舒张作用在大鼠和绵羊中的效力明显降低。线描肌电图显示,血浆白蛋白对这种降压作用的丧失有贡献,这种作用通过修饰白蛋白的半胱氨酸巯基残基而被消除。高剂量的 glut-BDNIC 引起大鼠持续时间较长的低血压,这至少部分归因于其约 44 分钟的长循环半衰期。本研究表明 glut-BDNIC 是一种 HNO 供体,其血管活性作用受与血浆蛋白(如白蛋白)的半胱氨酸残基结合的调节。